2nd Circ. Refuses To Revive Complaints In Eliquis MDL

Law360 (March 26, 2019, 5:27 PM EDT) -- The Second Circuit on Tuesday upheld the dismissal of more than a dozen claims in multidistrict litigation alleging that Pfizer Inc. and Bristol-Myers Squibb Co. didn't warn consumers of the risks associated with the blood thinner Eliquis, saying the claims are barred by federal regulations.

The panel unanimously agreed with the district court judge's decision that the claims had been properly removed to federal court and that they were preempted by U.S. Food and Drug Administration labeling rules.

The companies were facing an MDL claiming the drug's labels need warnings about the risk of internal bleeding, that dosages need to be...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Attached Documents

Related

Sections

Case Information

Case Title

Subscribers Only

Case Number

Subscribers Only

Court

Appellate - 2nd Circuit

Nature of Suit

4367 Torts

Date Filed

August 25, 2017

Law Firms

Companies

Government Agencies

Judge Analytics